Price increases for functional polymers for pharmaceutical applications
The Pharma polymers business line, part of Evonik Röhm GmbH, a subsidiary of Evonik Industries AG, will implement price increases for its methyl methacrylate-based polymers for pharmaceutical applications by up to 12% for their global EUDRAGIT® business, effective January 1, 2011.
The company’s priority is to enhance the quality and availability of supply and services. In this context significant investments were made to improve reliability, and to satisfy more stringent regulatory requirements. Additionally, increased wages and raw material costs are already above pre 2009 levels.
These investments will further improve the company’s infrastructure, strengthen business continuity and create competitive advantages for its pharmaceutical customers.
Other news from the department price development

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.